eneration switch' within all of us can be accomplished by our proprietary E-CEL Technology—a series of genetically-modified human endothelial cells. E-CEL Technology is potentially applicable to every tissue/organ in the body. Recently, we were awarded a $3.5M 'clinical track' grant from the California Institute

r) Weill Cornell Medical College Memorial Sloan Kettering Cancer Center,. • Disease Focus: Sickle Cell Anemia • Purpose: • Combine Angiocrine's E-CEL Technology with Sloan Kettering's gene correction technology to develop a curative therapy for sickle cell disease • Funds research, pre-clinical development